Huang Li-Bin, Yang Ting-Han, Yang Lie, Yu Yong-Yang, Wang Zi-Qiang, Wang Cun, Zhou Zong-Guang
Department of Gastrointestinal Surgery, West China Hospital and State Key Laboratory of Biotherapy, Sichuan University, Chengdu, China.
Medicine (Baltimore). 2020 Jun 26;99(26):e20693. doi: 10.1097/MD.0000000000020693.
The aim of this systematic review and meta-analysis is to assess the efficacy of adjuvant chemotherapy in patients with stage IIB/C CRC and defective mismatch repair (dMMr) status, and to evaluate what is the determinant risk factor for adjuvant chemotherapy in those patients.
A systematic search of PubMed, EMBASE, Web of science, Cochrane Library databases will be performed. All RCTs published in electronic databases from inception to March 19, 2020, with language restricted in English will be included in this review study. Two reviewers will independently perform the Study selection, data extraction, quality assessment, and assessment of risk bias and will be supervised by third party. Outcomes consisted of overall survival, progression-free survival and sufficient information to extract hazard ratios and their 95% confidence intervals and it will be calculated to present the prognostic role of adjuvant chemotherapy in patients with stage IIB/C CRC and dMMR status using Review Manager version 5.3 when there is sufficient available data.
The results of this systematic review and meta-analysis will be submitted to a peer-reviewed journal for publication.
This study will summarize up-to-date evidence to assess the efficacy of adjuvant chemotherapy in patients with stage IIB/C CRC and dMMR status and provide a scientific and practical suggestions for treatment decision-making.
This protocol has been registered on the International Platform of Registered Systematic Review and Meta-Analysis Protocols (INPLASY) with a registration number of INPLASY202050019.
本系统评价和荟萃分析的目的是评估辅助化疗对IIB/C期结直肠癌（CRC）且错配修复缺陷（dMMR）患者的疗效，并评估这些患者辅助化疗的决定性危险因素。
将对PubMed、EMBASE、科学网、Cochrane图书馆数据库进行系统检索。纳入本综述研究的是从创刊至2020年3月19日在电子数据库中发表的所有随机对照试验（RCT），语言限制为英语。两名研究者将独立进行研究选择、数据提取、质量评估以及风险偏倚评估，并由第三方监督。结局包括总生存期、无进展生存期以及提取风险比及其95%置信区间的充分信息，当有足够的可用数据时，将使用Review Manager 5.3版计算并呈现辅助化疗对IIB/C期CRC和dMMR患者的预后作用。
本系统评价和荟萃分析的结果将提交给同行评审期刊发表。
本研究将总结最新证据，以评估辅助化疗对IIB/C期CRC和dMMR患者的疗效，并为治疗决策提供科学实用的建议。
本方案已在国际注册系统评价和荟萃分析方案平台（INPLASY）上注册，注册号为INPLASY202050019。
